Natixis Trims Stock Position in The Cigna Group (NYSE:CI)

Natixis lowered its position in shares of The Cigna Group (NYSE:CI) by 98.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,560 shares of the health services provider’s stock after selling 247,993 shares during the period. Natixis’ holdings in The Cigna Group were worth $1,293,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Seizert Capital Partners LLC grew its stake in The Cigna Group by 195.8% in the 4th quarter. Seizert Capital Partners LLC now owns 32,150 shares of the health services provider’s stock worth $9,627,000 after buying an additional 21,280 shares in the last quarter. Roman Butler Fullerton & Co. lifted its holdings in shares of The Cigna Group by 61.4% in the 4th quarter. Roman Butler Fullerton & Co. now owns 9,307 shares of the health services provider’s stock worth $2,772,000 after acquiring an additional 3,539 shares during the last quarter. TFO Wealth Partners LLC lifted its holdings in shares of The Cigna Group by 98,980.0% in the 4th quarter. TFO Wealth Partners LLC now owns 4,954 shares of the health services provider’s stock worth $1,497,000 after acquiring an additional 4,949 shares during the last quarter. Ellsworth Advisors LLC bought a new stake in shares of The Cigna Group in the 4th quarter worth approximately $4,377,000. Finally, Sapient Capital LLC bought a new stake in shares of The Cigna Group in the 4th quarter worth approximately $2,811,000. Hedge funds and other institutional investors own 86.99% of the company’s stock.

Insider Transactions at The Cigna Group

In other news, SVP Hoeltzel Mary T. Agoglia sold 5,946 shares of the business’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $348.71, for a total value of $2,073,429.66. Following the transaction, the senior vice president now owns 2,595 shares of the company’s stock, valued at $904,902.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, SVP Hoeltzel Mary T. Agoglia sold 5,946 shares of the business’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $348.71, for a total value of $2,073,429.66. Following the sale, the senior vice president now directly owns 2,595 shares in the company, valued at $904,902.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Noelle K. Eder sold 10,700 shares of The Cigna Group stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $348.47, for a total value of $3,728,629.00. Following the completion of the sale, the insider now directly owns 15,824 shares in the company, valued at approximately $5,514,189.28. The disclosure for this sale can be found here. Insiders sold a total of 22,988 shares of company stock valued at $7,975,726 over the last 90 days. Company insiders own 0.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on CI. Oppenheimer boosted their price objective on shares of The Cigna Group from $370.00 to $400.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Robert W. Baird initiated coverage on shares of The Cigna Group in a report on Thursday, May 30th. They set an “outperform” rating and a $388.00 price target for the company. Baird R W upgraded shares of The Cigna Group to a “strong-buy” rating in a report on Thursday, May 30th. StockNews.com lowered shares of The Cigna Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 20th. Finally, Piper Sandler assumed coverage on shares of The Cigna Group in a report on Wednesday, June 26th. They set an “overweight” rating and a $400.00 price target for the company. Two investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $376.20.

The Cigna Group Stock Performance

Shares of NYSE CI traded down $1.22 during trading on Thursday, reaching $340.99. 775,038 shares of the company traded hands, compared to its average volume of 1,566,978. The firm has a 50 day simple moving average of $334.84 and a 200-day simple moving average of $337.25. The Cigna Group has a 52-week low of $253.95 and a 52-week high of $365.71. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 0.75. The stock has a market capitalization of $96.87 billion, a PE ratio of 28.10, a P/E/G ratio of 1.03 and a beta of 0.52.

The Cigna Group (NYSE:CI) last posted its quarterly earnings data on Thursday, May 2nd. The health services provider reported $6.47 earnings per share for the quarter, beating analysts’ consensus estimates of $6.17 by $0.30. The Cigna Group had a return on equity of 17.24% and a net margin of 1.76%. The firm had revenue of $57.25 billion for the quarter, compared to analysts’ expectations of $56.59 billion. During the same period in the previous year, the firm earned $5.41 EPS. The business’s quarterly revenue was up 23.2% on a year-over-year basis. Equities research analysts anticipate that The Cigna Group will post 28.47 earnings per share for the current year.

The Cigna Group Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 19th. Shareholders of record on Wednesday, September 4th will be issued a dividend of $1.40 per share. The ex-dividend date of this dividend is Wednesday, September 4th. This represents a $5.60 dividend on an annualized basis and a yield of 1.64%. The Cigna Group’s dividend payout ratio is presently 45.98%.

The Cigna Group Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.